Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Medical Affairs Reputations: Cancer Pain (US) 2017

Product Code:
596200908
Publication Date:
June 2017
Format:
PPTX
Price:
€5925

Disappointing scores show that medical affairs teams need to up their game

The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a lacklustre performance in the past 6 months. Their ratings on individual services barely crept into positive territory, and even though they’re contacting doctors a little too often, they’re failing to deliver the information doctors need. In other words, there’s plenty of room for improvement, and a motivated team can seize the opportunity to leap ahead of the competition.

Find out what your team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (US)

Comparing 6 major cancer pain treatments from Endo Pharmaceuticals, Insys Therapeutics, Mallinckrodt, Purdue Pharma, and Teva, this report reveals:

  • How doctors rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important, and what you can do to improve them.
  • How, and how often doctors want to meet with your team.

That’s actionable information you can use to turn your team into one that doctors rely on.

Interested in the European market? Click here to see the EU5 Edition? Click here to see the EU report.

Request sample pages

Top Takeaways

  • Scores are so-so: Performance and satisfaction ratings for individual medical affairs services are neutral to somewhat positive.
  • No one brand stands out: Most teams earned similar overall quality scores. Performance and satisfaction ratings are also similar.
  • Specific improvements needed: 5 of the surveyed teams need to improve between 1 and 3 specific services.
  • Over 40% of doctors say teams could do a better job of providing information: They identified 4 ways teams can improve, and highlighted 3 specific types of information they want more of.
  • Teams may be over-communicating: Doctors tend to want to hear from teams less often than teams are contacting them.
  • Time to pick up the pace: Only one team interacted with more than 65% of the surveyed doctors in the past 6 months.

Insight into Medical Affairs Teams for These Cancer Pain Treatments

  • Actiq (fentanyl transmucosal; Teva)
  • Exalgo (hydromorphone CR; Mallinckrodt)
  • Opana (oxymorphone IR; Endo Pharmaceuticals)
  • Opana ER (oxymorphone ER; Endo Pharmaceuticals)
  • OxyContin (oxycodone CII; Purdue Pharma)
  • Subsys (fentanyl sublingual; Insys Therapeutics)

An Expert-designed Competitive View of Your Medical Affairs Teams

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 6 medical affairs teams—answering important questions like: 

What do doctors need?

  • How, and how often are doctors using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team’s interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Expert Knowledge

We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with cancer pain in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the past 6 months.

We conducted the survey between June 1st and 7th, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved